Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000154
Chunk: 19

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 19
---
     |           | -226.9 |     |        | -433.2 |
| Net increase in cash and cash equivalents                     |     |             |  425.8 |     |           |  285.4 |     |        | -140.3 |
| Cash and cash equivalents at the beginning of the year        |     |             |  457.8 |     |           |  385.1 |     |        |  -72.7 |
| Effects of exchange rate changes on cash and cash equivalents |     |             |  -24.6 |     |           |   10.9 |     |        |   35.5 |
| Cash and cash equivalents at the end of the period            |     |             |  859.0 |     |           |  681.5 |     |        | -177.5 |

#### Net Cash from Operating Activities
Net Cash from Operating Activities was JPY 593.7 billion ( JPY +142.4 billion ). The increase was mainly due to favorable impacts from Changes in Assets and Liabilities primarily driven by changes in Trade and Other Receivables, as well as Trade and Other Payables. This increase was partially offset by unfavorable impacts resulting from Net Profit for the Period adjusted for non-cash items and other adjustments.

#### Net Cash used in Investing Activities
Net Cash used in Investing Activities was JPY 81.3 billion ( JPY -150.5 billion ). The decrease was mainly due to a decrease in cash outflow used in Acquisition of Intangible Assets, Acquisition of Option to License, and Acquisition of Investments as well as an increase in Proceeds from Sales of Business, Net of Cash and Cash Equivalents Divested.

#### Net Cash from (used) in Financing Activiti

#### es
Net Cash used in Financing Activities was JPY 226.9 billion ( JPY +433.2 billion) . The increase was mainly driven by lower net cash inflows from the issuance and repayments of bonds and long-term loans, as well as an increase in Acquisition of Treasury Shares during the six-month period ended September 30, 2025, and Proceeds from the Settlement of Cross Currency Interest Rate Swaps related to Bonds and Loans recorded during the six-month period ended September 30, 2024.

<div align='center'>- 13 -</div>

Translation for reference purpose only

### (4) Research & Development Activities and Results
Research and development expenses